Dr. Farrah B. Khan

Hematology Oncology | Oncology
111 Colchester Ave, 
Burlington, VT 
Accepting New Patients
Offers Telehealth
111 Colchester Ave, 
Burlington, VT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Farrah Khan is a Hematologist Oncology specialist and an Oncologist in Burlington, Vermont. Dr. Khan is rated as an Experienced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Endoscopy. Dr. Khan is currently accepting new patients.

Her clinical research consists of co-authoring 15 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Porter Hospital, Inc
Northwestern Medical Center Inc
Champlain Valley Physicians Hospital Medical Ctr
Univ. Of Vermont - Fletcher Allen Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNIVERSITY OF VERMONT MEDICAL CENTER INC
111 Colchester Ave, Burlington, VT 05401
Other Locations
UNIVERSITY OF VERMONT MEDICAL CENTER INC
1 S Prospect St, Burlington, VT 05401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

15 Total Publications

Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC.
Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC.
Journal: JTO clinical and research reports
Published: May 26, 2023
Similar Doctors
Advanced in BRCA Positive Breast Cancer
Dr. Kara K. Landry
Hospital Medicine | Oncology
Advanced in BRCA Positive Breast Cancer
Dr. Kara K. Landry
Hospital Medicine | Oncology

University Of Vermont Medical Center Inc

111 Colchester Ave, 
Burlington, VT 
 (0.1 miles away)
802-847-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kara Landry is a Hospital Medicine specialist and an Oncologist in Burlington, Vermont. Dr. Landry is rated as an Advanced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, DICER1 Syndrome, and HER2 Negative Breast Cancer. Dr. Landry is currently accepting new patients.

Experienced in BRCA Positive Breast Cancer
Dr. Marc S. Greenblatt
Oncology | Hematology
Experienced in BRCA Positive Breast Cancer
Dr. Marc S. Greenblatt
Oncology | Hematology

University Of Vermont Medical Center Inc

1 S Prospect St, 
Burlington, VT 
 (0.4 miles away)
802-847-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Greenblatt is an Oncologist and a Hematologist in Burlington, Vermont. Dr. Greenblatt is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, Salpingo-Oophorectomy, and Bone Marrow Aspiration. Dr. Greenblatt is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khan's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 17 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile